David J. Lennon — President, Novartis Gene Therapies
David J. Lennon, Ph.D., has been President of Novartis Gene Therapies (formerly AveXis) since 2018.
Mr. Lennon previously was General Manager of Novartis Oncology in Japan from 2017 to 2018. During his 15-year career at Novartis, he has held additional positions, including Vice President and Head of the Solid Tumors franchise for Novartis Oncology in the United States in 2017; Vice President and Head of the Lung, Melanoma and Neuroendocrine Tumors franchise for Novartis Oncology in the US from 2015 to 2017; Head of the Cardio-Metabolic unit for the Greater China region from 2014 to 2015; Chief Marketing Officer of the Greater China region for Novartis Pharmaceuticals from 2012 to 2014; and Vice President and Head of Marketing for the US Neurology and Psychiatry business from 2009 to 2011.
Mr. Lennon holds a doctorate in molecular medicine from Weill Cornell Medicine in the US, and a bachelor’s degree in biophysics from Columbia University in the US.
